Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Impact · against what's priced in

Positive clinical and translational data for icovamenib and the expansion of the BMF-650 study create significant upside for BMEA. The data suggests a broader therapeutic utility for icovamenib in obesity and type 1 diabetes, while the titration study aims to improve the competitive profile of its oral GLP-1 candidate.

BMEA+0.70: No priced-in read yet

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

What matters in this story

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

What matters in this story

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

How each ticker is affected

Track these names every morning.

Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action

BMY Reports Mixed Phase III Trial Results, Stock Down

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Haydale shares drop 12% as revenue falls short of expectations

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

What matters in this story

Next reads from the same story arc

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

What matters in this story

Next reads from the same story arc

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

How each ticker is affected

Track these names every morning.

Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action

BMY Reports Mixed Phase III Trial Results, Stock Down

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Haydale shares drop 12% as revenue falls short of expectations